Mr Mrs Miss Ms Dr Other

Dr
Fiona
Christie

Senior Patent Attorney

Leeds Office

Chemistry

Telephone. +44(0) 113 233 0100
Email. fchristie@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.
Vcard

Experience

Since joining HGF in 2014, Fiona has worked on drafting and prosecuting patent applications in a range of practice areas in the chemical field including pharmaceuticals, physical chemistry and nanomaterials.

Prior to joining HGF, Fiona obtained a First Class MSci in Forensic and Analytical Chemistry from the University of Strathclyde in 2009, during which she undertook a one-year industrial placement at Pfizer.

Fiona then moved to Cambridge University to accept a place on the Nanoscience and Technology Doctoral Training Centre. Fiona's doctoral research involved investigating routes to understanding the aggregation behaviour of insulin through the use of supramolecular chemistry. Following the submission of her thesis, Fiona completed a short research internship at the Ecole Normale Superieure in Paris, France working towards the manipulation of particle deposition in evaporating droplets.

Fiona qualified as a Chartered Patent Attorney and as a European Patent Attorney in 2019.

Specialisms

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

MSCI

Forensic and Analytical Chemistry, University of Strathclyde, 2009

PHD

Chemistry, University of Cambridge, 2014

POSTGRADUATE DIPLOMA OR CERTIFICATE

PGCert IP, University of Bournemouth

Related News

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

The concept of ‘overall impression’ in UK and EU Registered Design Law

 

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us